UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 
 WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT 
Pursuant to Section 13 or 15(d) of
The Securities and Exchange Act of 1934 
Date of Report (Date of earliest event reported) April 15, 2009
 ____________________
INTELGENX TECHNOLOGIES CORP.
 (Exact Name of Registrant as Specified in Charter)

Delaware	000-31187	87-0638336	
(State or other jurisdiction	(Commission File No.)	(IRS Employer ID)	
of incorporation)	 	 	
 	 	 	
6425 Abrams, Ville Saint Laurent, Quebec, H4S 1X9 Canada	
(Address of principal executive offices and Zip Code)	
 	
(514) 331-7440	
(Registrant's telephone number, including area code)	
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
£      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02
Election of Director
The Company confirms that, effective April 8, 2009, Mr. Bernd Melchers accepted the appointment of the Board of Directors to serve as a director of IntelGenx Technologies Corp. until the next annual meeting of the shareholders of the Company or until his successor is duly elected and qualified. The appointment of Mr. Melchers is subject to TSX-Venture approval.
Mr. Melcher’s background is as follows:
From January 2001 until December 2004 Mr. Melchers was Chief Financial Officer at 3M Dyneon GmbH & Co. KG, Germany.  Prior to this he was, from July 1995 to December 2000, Controller at the European Business Center of 3M Medical Markets Europe in Belgium.
Mr. Melchers retired from his position at 3M Dyneon Group in 2004 and currently provides consulting services for property management in Germany. 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Item 9.01
Exhibits

Exhibit
No.	Description	
 	 	
99.1	Press Release dated April 15, 2009	
 
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 	INTELGENX TECHNOLOGIES CORP.	

By: /s/	Horst Zerbe                                         	
 	Horst Zerbe	
Date: April 15, 2009	President and Chief	
 	Executive Officer	

Exhibit 99.1

IntelGenx Announces Appointment of New Director
SAINT LAURENT, QUEBEC, – April 15, 2009 - IntelGenx Technologies Corp. (TSX:IGX) OTCBB:IGXT) ("IntelGenx"), a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems, announced today that Mr. Bernd Melchers has accepted his appointment to serve on the Company’s Board of Directors. The appointment of Mr. Melchers is subject to the approval of the TSX-Venture.
Mr. Melchers is a 30-year veteran of the pharmaceutical industry with extensive hands-on international experience in corporate financial management. Most recently he was Global Chief Financial Officer of the Dyneion Group in Frankfurt, Germany, a subsidiary of 3M Corporation headquartered in Minnesota. Previously, he served as the European Controller of 3M Medical Markets at the 3M Europe Headquarter located in Brussels, Belgium. Prior to this Mr. Melchers held various senior financial positions at the Medical-Surgical Division of 3M at their headquarters in St. Paul, Minnesota, at 3M Health Care Products, Germany, and at 3M Pharmaceutical Products, Germany. Mr. Melchers also brings a wealth of international team management skills and leadership experience.
Mr. Melchers retired from his position at the Dyneion Group in 2004 and currently provides property management consulting services to private clients in Germany. He currently resides in Bad Homburg, Germany
Dr. Horst G. Zerbe, chairman and CEO of IntelGenx stated, “We are very pleased to add the support of Bernd Melchers to our Board. His extensive and comprehensive international experience in financial and general management will greatly strengthen the board of directors and the Company. At the same time, we wish to thank Dr. David Coffin-Beach for his invaluable contributions during his term as a director of this Company.”
Mr. Melchers will replace Dr. David Coffin-Beach who resigned from the board of directors on March 17, 2009 for personal reasons.
ABOUT INTELGENX CORP.:
IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of pain, hypertension, osteoarthritis, and depressive disorders. More information is available about the company at www.intelgenx.com.
CONTACT INFORMATION:
IntelGenx Corp.
Dr. Horst G. Zerbe, President and CEO
T: 514-331-7440 (ext. 201)
F: 514-331-0436
horst@IntelGenx.com
www.intelgenx.com
The TSX Venture Exchange and OTCBB do not accept responsibility for the adequacy or accuracy of this release.